Knott David M Jr Has $3.31 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Knott David M Jr raised its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 15.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 440,000 shares of the biotechnology company's stock after buying an additional 58,000 shares during the period. BioCryst Pharmaceuticals makes up about 1.2% of Knott David M Jr's investment portfolio, making the stock its 15th largest holding. Knott David M Jr owned approximately 0.21% of BioCryst Pharmaceuticals worth $3,309,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Schroder Investment Management Group lifted its stake in BioCryst Pharmaceuticals by 523.9% during the fourth quarter. Schroder Investment Management Group now owns 522,657 shares of the biotechnology company's stock valued at $3,936,000 after buying an additional 438,887 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in shares of BioCryst Pharmaceuticals by 34.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 26,442 shares of the biotechnology company's stock valued at $199,000 after acquiring an additional 6,840 shares in the last quarter. Norges Bank purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $3,947,000. Prudential Financial Inc. boosted its stake in BioCryst Pharmaceuticals by 10.2% in the 4th quarter. Prudential Financial Inc. now owns 983,033 shares of the biotechnology company's stock worth $7,392,000 after purchasing an additional 90,603 shares during the period. Finally, Vanguard Group Inc. grew its position in BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after purchasing an additional 1,583,826 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several analysts have recently commented on BCRX shares. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, Evercore ISI boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.57.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX traded down $0.10 during mid-day trading on Thursday, reaching $7.33. The stock had a trading volume of 3,074,275 shares, compared to its average volume of 2,772,637. The stock has a market cap of $1.53 billion, a P/E ratio of -12.02 and a beta of 1.84. The business's 50 day moving average is $8.16 and its 200 day moving average is $7.81. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the prior year, the company earned $0.28 EPS. The company's quarterly revenue was up 40.8% compared to the same quarter last year. Equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.